Beijing CAS Microneedle Technology, Ltd. (CASMN) is a platform enterprise focused on the R&D and industrialization of polymer microneedle formulations. The company provides pharmaceutical companies, biotechnology firms, and health-industry clients with one-stop technical solutions spanning microneedle formulation feasibility assessment, formulation development, process optimization, pilot scale-up, and scaled manufacturing.

Founded in 2018, CASMN is a technology-transfer startup originating from the Institute of Physical Chemistry, Chinese Academy of Sciences (CAS). It has been recognized as a National High-Tech Enterprise, a Beijing SRDI ("Specialized, Sophisticated, Differentiated, and Innovative") SME, and a candidate for the National Intellectual Property Powerhouse demonstration program. The company is deeply engaged in the full-chain R&D, pilot scale-up, and scaled manufacturing of flexible soluble microneedle transdermal technology, with business spanning five domains: innovative pharmaceuticals, medical devices, functional skincare, daily-use products, and microneedle equipment. It offers end-to-end CRO/CMO/CDMO/ODM customized services, closing the full translation chain from laboratory research results to market-ready products.

Drawing on 20+ years of CAS research in microneedle transdermal drug delivery, CASMN has built a dual industrial layout of "Beijing R&D and Pilot Base + Chongqing Scaled Manufacturing Base," supported by a postdoctoral research workstation and a CAS joint laboratory. It serves as the lead drafting unit of China's first "Soluble Microneedle Patch" group standard and has filed 70+ domestic and international patents.